Phase II, trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 84, Issue 1, 2002, Pages 32-35

  Plaxe, Steven C ^a   Blessing, John A ^b   Bookman, Michael A ^c   Creasman, William T ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Ovarian cancer; Pyrazoloacridine

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; CARBOPLATIN; CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; PLATINUM COMPLEX;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CARDIOVASCULAR DISEASE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; FEVER; HUMAN; LEUKOPENIA; LUNG TOXICITY; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

EID: 0036141074     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6441     Document Type: Article

References (16)

1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
2. Treatment of recurrent ovarian cancer: Increasing options, "recurrent results"
3. Recurrent ovarian carcinoma: Retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent
4. Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population
5. Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design of phase II trials
6. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II
7. Current status of pyrazoloacridine as an anticancer agent
8. Antitumor efficacy of PD115943 (NSC 366140) against solid tumors of mice
9. Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro
10. Phase and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent on single-dosing and multiple-dosing schedules
11. Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma
12. Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma
13. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study
14. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study
15. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group study